Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

July 1, 2019

Phase 3 Trial of Topsalysin, Potential Treatment for Localized Prostate Cancer, Planned for Europe

News

The European Medicines Agency (EMA) has approved Sophiris Bio’s design for a Phase 3 trial to evaluate the potential of topsalysin (PRX302), an investigative agent for localized prostate cancer. The ... Read more

June 13, 2019June 13, 2019

Study Shows How Prostate Cancer Cells Mimic Bone When They Metastasize

News

Prostate cancer cells can activate genes associated with bone formation and mimic bone cells’ behavior, allowing them to spread into bones. Those findings by by Duke University researchers, have revealed ... Read more

June 3, 2019

American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer

News

Funded by a $380,000 grant from the National Cancer Institute, researchers at the University at Buffalo (UB) in New York and Moscow State University in Russia are collaborating to study ... Read more

May 22, 2019May 22, 2019

Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows

News

Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial shows. ... Read more

May 6, 2019

Janssen Seeks Expanded FDA Approval of Erleada to Treat Metastatic Castration-sensitive Prostate Cancer

News

Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) seeking the approval of its androgen receptor inhibitor Erleada (apalutamide) for patients with metastatic castration-sensitive prostate cancer (CSPC). ... Read more

May 2, 2019

Essa Pharma’s Androgen Receptor Inhibitor, EPI-7386, Selected as Lead Candidate Therapy

News

EPI-7386, a new androgen receptor inhibitor, was selected as Essa Pharma‘s lead candidate therapy for metastatic castration-resistant prostate cancer (mCRPC), the company announced. The company’s decision was supported by early ... Read more

April 3, 2019

Radioactive Compound Shows Promise as Therapy for Metastatic Castration-resistant Prostate Cancer Patients

News

Treatment with the radioactive molecule lutetium-177-PSMA-617 (LuPSMA), which binds to the prostate-specific membrane antigen, is a potential therapeutic strategy for patients with metastatic castration-resistant prostate cancer (CRPC), results from a ... Read more

April 1, 2019

Targazyme Gets Funding for Trial Testing TZ101 for Erectile Dysfunction in PC Patients

News

Targazyme has been granted an award from the The Sexual Medicine Society of North America that will fund a clinical trial testing the company’s stem cell-based product TZ101 to reverse ... Read more

March 28, 2019

Three Keytruda Combinations Show Signs of Efficacy in Metastatic CRPC

News

Combining the immune checkpoint inhibitor Keytruda (pembrolizumab) with either a PARP inhibitor, chemotherapy, or hormone therapy led to promising signs of activity in metastatic castration-resistant prostate cancer (mCRPC) patients in ... Read more

March 25, 2019

Robotic Prostatectomy is Popular, but Not Superior to Other Options, Study Says

News

While current clinical data support no difference in the survival outcomes of prostate cancer patients after robotic surgery or radiation therapy, men tend to prefer surgery after consulting with their ... Read more